Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna’s personalized mRNA vaccine, given with Keytruda, cut melanoma recurrence in a large trial — a big validation of mRNA for cancer.
Doctors hope the approach could be adapted to many tumor types, with multiple late‑stage trials and more results expected in the next few years.
The combo showed no new safety signals versus Keytruda alone, which may change how doctors weigh post‑surgery treatment decisions.